But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...

Eli Lilly’s LLY first-quarter revenue grew 45%, as combined sales for Mounjaro (diabetes) and Zepbound (obesity) rose ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Eli Lilly on Thursday reported first-quarter profit above Wall Street estimates, helped by strong sales of its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro. On an adjusted basis ...

From STAT’s Jason Mast: Moderna said this morning in its earnings report it planned to cut costs by around $1.5 billion by ...

Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...

Ricks said reshoring manufacturing capacity for older essential medicines is “a valid thing,” adding that Eli Lilly is “happy ...

Eli Lilly stock has been a big-time winner ... retaliatory tariffs from other countries could also weigh on Lilly's business; the company could start to see diminished brand equity in ...

Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as demand for its weight loss and diabetes injections soars and the company ...

While Eli Lilly has a significant presence in the U.S., bringing its developing treatment to market will require stable business conditions. The Indianapolis company on Thursday said its ...

From late 2020 to the summer of 2024, Eli Lilly & Co ... Billions Since 2016, Lilly’s revenue grew by 60% but income grew by 91%. Typically, you would not expect a company growing at its ...

Eli Lilly's new experimental pill called orforglipron, helped patients shed weight and control blood sugar as well as blockbuster drug Ozempic in a trial of diabetes patients, and the company ...